StockNews.AI
LFMD
StockNews.AI
14 hrs

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD

1. Faruqi & Faruqi investigates claims against LifeMD over potential securities violations. 2. LifeMD allegedly overstated competitive position and revenue guidance for 2025. 3. The stock fell 44.8% after adjusted revenue guidance was announced. 4. October 27, 2025, is the deadline to seek lead plaintiff status. 5. Investors are encouraged to reach out with information on LifeMD's conduct.

7m saved
Insight
Article

FAQ

Why Very Bearish?

LifeMD's stock suffered a sharp drop of 44.8% recently due to lowered guidance. Historical examples show significant declines often lead to prolonged recovery periods.

How important is it?

Legal actions and stock performance issues are directly related to investor sentiment and stock volatility. The potential for significant losses could deter new investors.

Why Short Term?

The immediate effects from class action news can reduce investor confidence sharply. However, if litigation resolves favorably, a long-term recovery could occur.

Related Companies

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options If you suffered losses in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] , /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) and reminds investors of the October 27, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants materially overstated LifeMD's competitive position; (2) Defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, Defendants' statements about LifeMD's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On August 5, 2025, after the market closed, LifeMD reported its financial results for the second quarter of 2025. In this announcement, LifeMD announced revised guidance. Among other metrics, LifeMD stated that it was expecting total revenue in the range of $250 to $255 million, compared with previous guidance of $268 to $275 million.On this news, LifeMD's stock plummeted 44.8% on August 6, 2025.The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding LifeMD's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the LifeMD class action, go to www.faruqilaw.com/LFMD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.SOURCE Faruqi & Faruqi, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News